Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer

pharmafile | February 17, 2020 | News story | Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma 

New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable advanced or metastatic non-clear cell renal cell carcinoma (nccRCC).

The drug, developed in partnership with MSD, was tested in 31 participants who had not previously received chemo. The overall response rate recorded for the combo was 25.8% as measured using RECIST 1.1 guideline; eight patients achieved a partial response, but none recorded a complete response.

Furthermore, 58% were recorded as having stable disease, and the drug showed a 61.3% clinical benefit rate. Median progression-free survival was 9.23 months while estimable median overall survival was 15.64 months; however, the median duration of response could not be determined as it was not reached by the data cutoff in July 2019.

“NccRCC is a less studied subtype of the disease that encompasses a biologically varied group of tumour types with diverse prognoses and responses to therapy,” said Thomas Hutson, the study’s primary investigator and Director of the Genitourinary Oncology Program and Co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center.. “I was pleased to have been involved in this trial and look forward to continuing research to enhance our understanding of nccRCC.”

Dr Kirk Shepard, Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs for the Oncology Business Group at Eisai, also commented: “We are striving to improve care for people living with cancers with high unmet needs such as non-clear cell RCC. While there continue to be advancements in clear cell RCC, non-clear cell RCC continues to be an area where a strong need remains for more options, and we look forward to further exploring the potential this regimen may have for patients.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

Latest content